Impact Giving
Authored by Christopher C. Conway, Chief Philanthropy Officer & Executive Vice President of Strategic Communications
Indiana Biosciences Research Institute (IBRI) was built to solve big problems. We do that work every day, and we measure our progress. Yes, aspects of our scientific work aimed at tackling the biggest challenges may start small or seem esoteric, but this work is not abstract. Each day what happens in our labs is carefully documented, data is generated, and the work matters to people around the world. Curing diseases is a series of problems that urgently need to be solved, and we are ever mindful that every day counts.
Our goal at IBRI is continuous impact. So we measure our work and hold ourselves accountable to progress. Transparency and monitoring is a part of IBRI institutional culture and is foundational to the launch of our new impact giving campaign.
In the coming year, IBRI will be engaging with donors here in Indiana and around the world to secure funds for impact giving. Whether in Indianapolis, Los Angeles, or London, conversations with donors are almost always specific. Givers are spurred toward generosity for many reasons, and often, there is a personal connection. For those givers, cures cannot come fast enough. By encouraging donors to choose targets for support, we can fuel momentum and track the impact of these gifts. It’s a model that makes sense in an increasingly complex research ecosystem. Your support goes directly toward accelerating discoveries, not navigating bureaucracy.
When it comes to rare diseases, particularly pediatric cancers, time matters most of all. For these illnesses that impact a relatively small number of children, and their families, hope and help are vital because most research funding is pegged to population size. Historically, diseases which may be statistically marginal are underfunded, and targeted giving can vault over that barrier, adding more resources with more direct funding.
My job is to make sure that every potential donor, everywhere, is aware that as IBRI continues to unlock cures, the opportunities for direct impact are here, and now.
